Oruka Therapeutics, INC Schedule 13D activist filings

Fairmount Funds Management LLC and its affiliates have filed an amendment to their Schedule 13D, reporting changes in their beneficial ownership of Oruka Therapeutics, Inc. common stock.

Fairmount Funds Management LLC reports a 19.99% beneficial ownership stake in Oruka Therapeutics following a lock-up agreement.

Fairmount Funds Management LLC and affiliates increased their beneficial ownership in ORUKA THERAPEUTICS, INC. to 19.99% through a $5 million private placement.

Fairmount Funds Management LLC and its affiliates have filed an Amendment No. 3 to their Schedule 13D for ORUKA THERAPEUTICS, INC., updating their reported beneficial ownership percentage due to a change in the issuer's total outstanding common stock, while their actual shareholdings remain unchanged.